Strong Q3 FY26: revenue up 23%, PAT up 54.5% YoY for Dr. Agarwal's
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.3 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q3 FY26 consolidated total income up 21.9% YoY at INR 540 Cr, EBITDA INR 155 Cr (up 21.3%), PAT INR 44 Cr (up 54.5%). For 9M FY26, total income rose 20.8% to INR 1,548 Cr, EBITDA grew 23.6% to INR 440 Cr, PAT jumped 74.3% to INR 118 Cr. Network at 272 facilities with 238,283 surgeries. Board also approved new Ethiopia subsidiary, office shift within Chennai, and ending Idearx associate status.
Strong revenue and profit growth driven by network expansion and higher mature centre revenues. Likely positive for stock.